ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

The Correlation Between Decreased Ornithine Level and Alleviation of Rheumatoid Arthritis Patients Assessed by a Randomized, Placebo-Controlled, Double-Blind Clinical Trial of Sinomenine

Shi, Ying; Pan, Hu-Dan; Wu, Jian-Lin; Zou, Qing-Hua; Xie, Xin-Yi; Li, Hong-Gang; Zhou, Hua; Bian, Xi-Qing; Leng, Wen-Fei; Wang, Can-Jian; Wang, Ya-Feng; Fang, Yong-Fei*; Liu, Liang*广州中医药大学
Engineering2022-9DOI: 10.1016/j.eng.2021.04.014
4被引4阅读
引用收藏
分享

摘要

Sinomenine (SIN) is commonly used as part of rheumatoid arthritis (RA) therapy in China, but there is still no published evidence of the efficacy of SIN monotherapy. This work investigates the efficacy and safety of SIN in treating RA patients and analyzes the correlation between ornithine level and the alleviation of disease activity in RA patients. In this 24 week, randomized, placebo-controlled, double-blind clinical trial, people with mild to moderate RA were randomly assigned (1:1:1, stratified by hospital) to receive SIN (120 mg, twice daily), methotrexate (MTX) (10 mg per week), or SIN + MTX therapy. The primary out-come was the proportion of patients who achieved a 50% improvement in the American College of Rheumatology (ACR50) criteria at week 24 and who showed improvement according to the clinical dis-ease activity index (CDAI). In this prospective subgroup analysis, we also assessed whether the 24-week alterations of disease activity in the treatment group were significantly correlated to the levels of blood ornithine. Of the 135 enrolled participants, 38, 39, and 36 patients were treated with SIN, MTX, and SIN + MTX, respectively. In the SIN-treated group, 52.63% of patients achieved ACR50 after 24-weeks of treatment, which was comparable to the results in the MTX-treated and SIN + MTX-treated groups. Hepatic and gastrointestinal disorders were the main adverse events; however, the ratio of patients suf-fering from hepatic disorder in the SIN group (1/38) was much lower than that in the MTX (10/39) and SIN + MTX (8/36) groups. A total of 221 serum samples were collected at the four follow-up time points in the three treatments, and the levels of ornithine, citrulline, and arginine were obtained through ultra-high performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UHPLC-Q-TOF/ MS). The serum ornithine level decreased after the 24-week treatment along with a decrease in disease activity, and may reflect therapeutic responses with a sensitivity value of 80%. In conclusion, SIN revealed a comparable efficacy to MTX for treating RA patients, but with fewer side effects. In addition, the serum ornithine level was found for the first time to have a close correlation with the alleviation of RA, which shows the value of this measure as an assessment indicator of drugs in treating RA.(c) 2022 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

学科与关键词

关键词
Rheumatoid arthritisSinomenineEfficacySafetyInflammatory biomarker
相关
加载中…
  • Pharmacological mechanisms of sinomenine in anti-inflammatory immunity and osteoprotection in rheumatoid arthritis: A systematic review
    Li, Juan -Min; Yao, Yun-Da; Luo, Jin-Fang; Liu, Jian-Xin; Liu, Zhong-Qiu; Dong, Yan*; Xie, Ying*; Zhou, Hua*PHYTOMEDICINE, 2023, 121: 155114.
  • IDENTIFICATION OF NEW BIOMARKERS FOR SINOMENINE TREATMENT IN RHEUMATOID ARTHRITIS BASED ON BIOINFORMATICS ANALYSIS
    Shen, X.; Yanqun, L.; Guo, X.; Linfeng, W.; Zhang, J.; Feng, Z.
  • Sinomenine ameliorates collagen-induced arthritis in mice by targeting GBP5 and regulating the P2X7 receptor to suppress NLRP3-related signaling pathways
    Li, Juan-min; Deng, Hai-shan; Yao, Yun-da; Wang, Wei-ting; Hu, Jia-qin; Dong, Yan; Wang, Pei-xun; Liu, Liang; Liu, Zhong-qiu*; Xie, Ying*; Lu, Lin-lin*; Zhou, Hua*Acta Pharmacologica Sinica, 2023, 44(12): 2504-2524.被引 2
查看全部 →

发表信息

论文状态
公开发表
期刊
Engineering
发表日期
2022-09
卷期
第 16 卷
页码
93-99
DOI
10.1016/j.eng.2021.04.014
期刊收录
CAST-L
成果收录
SCIE
资助标注
Hunan Zheng Qing Pharmaceutical Group Co., Ltd.; Macao Science and Technology Development Fund [0032/2018/AFJ, 0003/2019/AKP, 0010/2020/A1, 001/2020/ALC]; Key Program in Emerging Industry of the Hunan Department of Science Technolog [2014GK1058]

作者

  • S

    Shi, Ying (第一作者)

  • P

    Pan, Hu-Dan

    2 · guangzhou univ chinese med

查看全部 13 位作者收起作者
  • W

    Wu, Jian-Lin

  • Z

    Zou, Qing-Hua

  • X

    Xie, Xin-Yi

  • L

    Li, Hong-Gang

  • Z

    Zhou, Hua

  • B

    Bian, Xi-Qing

  • L

    Leng, Wen-Fei

  • W

    Wang, Can-Jian

  • W

    Wang, Ya-Feng

  • F

    Fang, Yong-Fei (通讯)

  • L

    Liu, Liang (通讯)

    2 · guangzhou univ chinese med

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417